Hints and tips:
Related Special Reports
...Beyond its ProfoundBio acquisition, Genmab has used a number of licensing deals with larger pharmaceutical companies to develop its other drugs, working with AbbVie, Johnson & Johnson and Novartis....
...Miels said that the pharmaceutical company has since “rebuilt” its business in China....
...Novartis notched a 10 per cent increase in sales in 2023 as strong performance for its heart and arthritis medicines helped Europe’s second-largest pharmaceuticals company beat its guidance for the year....
...The pharmaceutical industry has no shortage of funds or motivation when it comes to improving drug discovery success rates using AI....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...Where doubts creep in is how Novartis will replace lost sales from 2027....
...Isomorphic Labs has partnerships with pharmaceutical companies Eli Lilly and Novartis....
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...But pharmaceutical companies can file several patents for single drugs at different times, delaying the entry of generic medicines....
Admonitions about staff trading in their employer’s shares may now need to be broadened
...Big share price moves in Europe this morning include Swiss pharmaceutical group Novartis, London-listed betting group Entain and French maker of rail infrastructure Alstom....
...focused Novartis”....
...Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform...
...The deal comes as pharmaceutical companies gather in San Francisco for an annual industry conference, with GSK rivals Johnson & Johnson, Novartis and Merck announcing acquisitions on Monday....
...Pharmaceutical companies must replenish their drugs pipeline before exclusivity rights on top-selling products expire....
...Shares in Novartis were up just over 3 per cent in early trading on Tuesday, but have languished this year....
...Swiss pharmaceutical giant Novartis has launched a $15bn share buyback programme after raising its outlook for the year on the back of strong sales....
..., and Merck and Novartis signing smaller deals on Monday....
...was so appalling, no one else bothered to invest capital to enter that space because it wasn’t an attractive market,” says Richard Saynor, chief executive of Sandoz, a generics manufacturer spun-out from Novartis...
...The US is the largest pharmaceutical market, mainly because it pays the most in the world for drugs....
...Novartis chief executive Vas Narasimhan said in 2021 that he believed the radioligand market could be worth up to $10bn....
...Ireland’s corporation tax receipts bounced back strongly in November after three months of falls, alleviating fears that a bonanza from international technology and pharmaceutical companies in the country...
...Also in the frame are the technology and pharmaceutical sectors. Their wealth of intellectual property makes them particularly adept at shifting profits....
...This is aided by the fact that groups such as Novartis are based in the city, soon to be joined by AstraZeneca....
International Edition